Latest Developments on Three Drug Discovery Programs Funded by Families of Spinal Muscular Atrophy.
June 19, 2009.

The Summer 2009 issue of “Compass” from Families of Spinal Muscular Atrophy is focused on Drug Discovery and Development programs for SMA.  In particular we are highlighting the latest news on the Families of SMA Funded Therapeutic Pipeline.

Families of SMA Therapeutic Pipeline:
FSMA is funding three distinct drug discovery programs:  1) Quinazolines to boost SMN2 expression; 2) Tetracyclines at Paratek Pharmaceuticals to correct SMN2 splicing; 3) Motor neuron replacement program at California Stem Cell and UCI. 
These three programs represent an investment of over $16 Million so far to build a SMA drug pipeline.

The three articles in this newsletter cover:

FSMA Quinazoline Program Update: Preparations Now Underway for a pre-IND Meeting with the FDA.
By Jill Jarecki, Ph.D., Research Director FSMA.

FSMA-Funded Project at Paratek Pharmaceuticals Moves into Next Phase with a Multi-Million Dollar NINDS Grant Award.
By Paul Higgins, Ph.D., Director, Inflammation Drug Discovery, Paratek Pharmaceuticals.

High Purity Human Motor Neurons for Treatment of SMA Type I.
By Chris Airriess, Ph.D., Chief Operating Officer, California Stem Cell, Inc.

Click the image below to download a copy:

Please call (800) 886-1762 or email info@fsma.org if you would like a hard copy of Compass mailed to you.
 
Click here to see more details on our research programs.

This new Compass is being released at the 25th Anniversary Conference.
Click here for details on the conference in Cincinnati.
We are expecting a record attendance this year of over 900 families and researchers!

Click here to visit the website for Paratek Pharmaceuticals.

Click here to visit the website for California Stem Cell, Inc.